The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA.
 
Yoon Ming Chin
Employment - Cancer Precision Medicine
 
Tomoko Shibayama
No Relationships to Disclose
 
Masumi Otaki
No Relationships to Disclose
 
Hiu Ting Chan
No Relationships to Disclose
 
Makiko Ono
No Relationships to Disclose
 
Yoshinori Ito
Research Funding - A2 Healthcare; AstraZeneca; Chugai Pharma; Covance; Daiichi Sankyo; Eisai; EPS Associates Co., Ltd.; Kiowa Kirin; Lilly; MSD; Novartis; PAREXEL; QVIA Services Japan; Taiho Pharmaceutical
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); PharmaMar (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Shinji Ohno
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Eisai
 
Yusuke Nakamura
Stock and Other Ownership Interests - OncoTherapy Science
Consulting or Advisory Role - OncoTherapy Science
Research Funding - Cancer Precision Medicine
 
Siew-Kee Kee Low
Consulting or Advisory Role - Cancer Precision Medicine
Research Funding - Novartis